Pembro-话题@MedSci

#Pembro#

98篇内容 | 2710人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1787030, encodeId=50f51e870302b, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Eur Urol Oncol：晚期肾细胞癌患者接受一线Pembrolizumab加Axitinib治疗时出现的肝脏毒性的特征和管理, objectType=article, longId=214935, objectId=823a21493535, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=823a21493535, replyNumber=0, likeNumber=82, createdTime=2021-09-07, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=823a21493535, moduleTitle=Eur Urol Oncol：晚期肾细胞癌患者接受一线Pembrolizumab加Axitinib治疗时出现的肝脏毒性的特征和管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=823a21493535)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787031, encodeId=62201e8703159, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Cancers：预测帕博利珠单抗（Pembrolizumab）治疗非小细胞肺癌患者持续应答的标志物和基因集, objectType=article, longId=215106, objectId=b85c215106cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b85c215106cc, replyNumber=0, likeNumber=96, createdTime=2021-08-06, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b85c215106cc, moduleTitle=Cancers：预测帕博利珠单抗（Pembrolizumab）治疗非小细胞肺癌患者持续应答的标志物和基因集, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b85c215106cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787019, encodeId=64f51e870192e, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J Clin Oncol：Pembrolizumab单抗作为晚期非透明细胞肾细胞癌患者一线治疗的开放标签、单臂、II期研究 , objectType=article, longId=207862, objectId=969e20e862ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=969e20e862ea, replyNumber=0, likeNumber=77, createdTime=2021-04-06, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=969e20e862ea, moduleTitle=J Clin Oncol：Pembrolizumab单抗作为晚期非透明细胞肾细胞癌患者一线治疗的开放标签、单臂、II期研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=969e20e862ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787020, encodeId=134a1e8702060, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Eur Urol：新辅助pembrolizumab治疗后残余膀胱癌的分子特征分析 , objectType=article, longId=209873, objectId=a5d52098e34a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5d52098e34a, replyNumber=0, likeNumber=70, createdTime=2021-05-20, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5d52098e34a, moduleTitle=Eur Urol：新辅助pembrolizumab治疗后残余膀胱癌的分子特征分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5d52098e34a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787029, encodeId=7b5e1e8702901, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Lung Cancer：Pembrolizumab+化疗对比 atezolizumab+化疗+/− 贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌（NSCLC）的疗效：匹配调整的间接比较分析, objectType=article, longId=214192, objectId=a0972141922d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0972141922d, replyNumber=0, likeNumber=100, createdTime=2022-04-22, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0972141922d, moduleTitle=Lung Cancer：Pembrolizumab+化疗对比 atezolizumab+化疗+/− 贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌（NSCLC）的疗效：匹配调整的间接比较分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0972141922d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787023, encodeId=42151e8702372, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, objectType=article, longId=212429, objectId=7a5c212429e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5c212429e5, replyNumber=0, likeNumber=82, createdTime=2021-07-07, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5c212429e5, moduleTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5c212429e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787022, encodeId=ad2b1e8702206, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果, objectType=article, longId=211056, objectId=5c43211056a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c43211056a3, replyNumber=0, likeNumber=83, createdTime=2021-07-05, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c43211056a3, moduleTitle=Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c43211056a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787015, encodeId=950c1e87015fb, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Pembrolizumab在罕见组织肉瘤中提供临床益处！, objectType=article, longId=201015, objectId=9615201015c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9615201015c4, replyNumber=0, likeNumber=73, createdTime=2021-07-01, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9615201015c4, moduleTitle=Pembrolizumab在罕见组织肉瘤中提供临床益处！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9615201015c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787009, encodeId=556c1e870093e, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J Clin Oncol：难治性转移去势抵抗性前列腺癌中Pembrolizumab的治疗研究 , objectType=article, longId=190258, objectId=2c14190258a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c14190258a9, replyNumber=0, likeNumber=55, createdTime=2020-12-01, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c14190258a9, moduleTitle=J Clin Oncol：难治性转移去势抵抗性前列腺癌中Pembrolizumab的治疗研究 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c14190258a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787008, encodeId=09e61e870080c, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=189823, objectId=597d18982326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597d18982326, replyNumber=0, likeNumber=67, createdTime=2020-10-06, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597d18982326, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597d18982326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787018, encodeId=f7661e87018e0, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗, objectType=article, longId=202368, objectId=85c8202368f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85c8202368f2, replyNumber=0, likeNumber=71, createdTime=2021-03-14, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85c8202368f2, moduleTitle=Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85c8202368f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787017, encodeId=14e31e87017fb, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=CAN04联合pembrolizumab治疗多种肿瘤：I期临床研究正在进行中, objectType=article, longId=201590, objectId=0d3c201590b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d3c201590b5, replyNumber=0, likeNumber=77, createdTime=2021-01-16, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d3c201590b5, moduleTitle=CAN04联合pembrolizumab治疗多种肿瘤：I期临床研究正在进行中, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d3c201590b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787012, encodeId=d5c01e8701270, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, objectType=article, longId=195301, objectId=db5919530147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db5919530147, replyNumber=0, likeNumber=78, createdTime=2021-05-10, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db5919530147, moduleTitle=ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db5919530147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787016, encodeId=2f801e87016dd, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Future Oncol：Pembrolizumab在肺癌中的治疗效果, objectType=article, longId=201423, objectId=b60d20142341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b60d20142341, replyNumber=0, likeNumber=66, createdTime=2020-10-10, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b60d20142341, moduleTitle=Future Oncol：Pembrolizumab在肺癌中的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b60d20142341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787014, encodeId=3dd81e87014d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Int J Clin Oncol：PembrolizumabVS化疗治疗复发性晚期尿道癌的疗效, objectType=article, longId=198492, objectId=2b63198492b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b63198492b1, replyNumber=0, likeNumber=77, createdTime=2021-06-19, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b63198492b1, moduleTitle=Int J Clin Oncol：PembrolizumabVS化疗治疗复发性晚期尿道癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b63198492b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787011, encodeId=05951e87011f9, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Eur Urol：分子亚型和免疫浸润对肌层浸润性膀胱癌新辅助Pembrolizumab治疗的病理响应和结果影响, objectType=article, longId=190995, objectId=3a86190995c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a86190995c8, replyNumber=0, likeNumber=80, createdTime=2020-09-04, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a86190995c8, moduleTitle=Eur Urol：分子亚型和免疫浸润对肌层浸润性膀胱癌新辅助Pembrolizumab治疗的病理响应和结果影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a86190995c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787013, encodeId=32081e870136c, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用, objectType=article, longId=197251, objectId=93ea19e25141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93ea19e25141, replyNumber=0, likeNumber=67, createdTime=2020-10-20, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93ea19e25141, moduleTitle=Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93ea19e25141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787001, encodeId=980b1e8700186, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=2019年SNO年会：DNX-2401与pembrolizumab联合治疗胶质母细胞瘤的II期研究取得积极结果, objectType=article, longId=183566, objectId=9e51183566d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e51183566d3, replyNumber=0, likeNumber=69, createdTime=2020-04-20, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e51183566d3, moduleTitle=2019年SNO年会：DNX-2401与pembrolizumab联合治疗胶质母细胞瘤的II期研究取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e51183566d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787007, encodeId=53f61e87007cf, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, objectType=article, longId=189176, objectId=3c381891e64b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c381891e64b, replyNumber=0, likeNumber=85, createdTime=2020-03-24, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c381891e64b, moduleTitle=J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c381891e64b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1787010, encodeId=70791e87010c0, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=lenvatinib联合KEYTRUDA（pembrolizumab）在晚期子宫内膜癌研究中获得积极结果, objectType=article, longId=190523, objectId=37e61905231f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37e61905231f, replyNumber=0, likeNumber=116, createdTime=2020-10-29, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37e61905231f, moduleTitle=lenvatinib联合KEYTRUDA（pembrolizumab）在晚期子宫内膜癌研究中获得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37e61905231f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Pembro

2020-05-29

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Eur Urol Oncol：晚期肾细胞癌患者接受一线Pembrolizumab加Axitinib治疗时出现的肝脏毒性的特征和管理

2021-09-07

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Cancers：预测帕博利珠单抗（Pembrolizumab）治疗非小细胞肺癌患者持续应答的标志物和基因集

2021-08-06

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J Clin Oncol：Pembrolizumab单抗作为晚期非透明细胞肾细胞癌患者一线治疗的开放标签、单臂、II期研究

2021-04-06

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Eur Urol：新辅助pembrolizumab治疗后残余膀胱癌的分子特征分析

2021-05-20

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Lung Cancer：Pembrolizumab+化疗对比 atezolizumab+化疗+/− 贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌（NSCLC）的疗效：匹配调整的间接比较分析

2022-04-22

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。

2021-07-07

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Liver Cancer：帕博利珠单抗（Pembrolizumab）二线应用于晚期肝癌疗效：来自KEYNOTE-240亚洲人群的亚组分析结果

2021-07-05

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Pembrolizumab在罕见组织肉瘤中提供临床益处！

2021-07-01

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J Clin Oncol：难治性转移去势抵抗性前列腺癌中Pembrolizumab的治疗研究

2020-12-01

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2020-10-06

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Lancet respir med：Pembrolizumab联合放疗用于转移性非小细胞肺癌患者的治疗

2021-03-14

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

CAN04联合pembrolizumab治疗多种肿瘤：I期临床研究正在进行中

2021-01-16

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

ASCO 2020 | Pembrolizumab或替代化疗在MSI-H / dMMR CRC中一线治疗的地位

2021-05-10

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Future Oncol：Pembrolizumab在肺癌中的治疗效果

2020-10-10

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Int J Clin Oncol：PembrolizumabVS化疗治疗复发性晚期尿道癌的疗效

2021-06-19

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Eur Urol：分子亚型和免疫浸润对肌层浸润性膀胱癌新辅助Pembrolizumab治疗的病理响应和结果影响

2020-09-04

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用

2020-10-20

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

2019年SNO年会：DNX-2401与pembrolizumab联合治疗胶质母细胞瘤的II期研究取得积极结果

2020-04-20

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

J Clin Oncol：Pembrolizumab与Bevacizumab治疗转移肾细胞肿瘤的Ib/II期临床试验

2020-03-24

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

lenvatinib联合KEYTRUDA（pembrolizumab）在晚期子宫内膜癌研究中获得积极结果

2020-10-29

科室
- - 订阅+
  - 更多科室
工具
服务